

September 5, 2016

Milestone Scientific Inc.
220 South Orange Avenue
Livingston, NJ 07039
USA

To:

Milestone Medical, Inc.
220 South Orange Avenue, Livingston,
New Jersey 07039, USA
Fax: 1-973-535-2829

Financial Supervision Commission
Plac Powstańców Warszawy 1
00-950 Warszawa
Fax: 48-22 262-55-32

Dear Sirs,


Pursuant to Article 69 section 2 point 2) of the Act of 29 July 2005 on Public Offering and the Conditions Governing the Introduction of Financial Instruments to Organized Trading and on Public Companies (the "**Act**"), I hereby notify that the notification made on June 17, 2016 **requires correction**. Namely, as a result of a share exchange agreement Milestone Scientific acquired 1,689,078 shares of Milestone Medical, Inc. (the "**Company**") entitling to exercise 1,689,078 votes at the Company's General Meeting of Shareholders, constituting 7.68 % of total number of votes at the Company's General Meeting of Shareholders, the share of Milestone Scientific Inc. has increased by more than 1%.

The acquisition of remaining shares as notified in the letter dated June 17, 2016 has not been completed due to the restrictions on issue of shares by Milestone Scientific imposed by the New York Stock Exchange. Consequently, Milestone Scientific expects that the acquisition of remaining shares would be completed in the first quarter of 2017. Milestone Scientific is also expecting the transfer of the Company's shares to its securities account as soon as it provides required documentation.

At present Milestone Scientific Inc. holds 19,900,000 shares of the Company, entitling to exercise 19,900,000 votes at the Company's General Meeting of Shareholders, constituting 90.45 % of total number of votes at the Company's General Meeting of Shareholders.

Milestone Scientific Inc. also confirms that it does not exclude a possibility to increase its stake in the Company in the course of next 12 months.

Additionally, Milestone Scientific Inc. confirms that there are no persons or entities referred to in Article 87 section 1 point 3 c) of the Act.


Joseph D'Agostino